Preferred Label : Anti-CEA/Anti-CEACAM6 Antibody-drug Conjugate EBC-129;
NCIt synonyms : Anti-CEACAM5/Anti-CEACAM6 Antibody-drug Conjugate EBC-129; Anti-CEA/Anti-CEACAM6 ADC EBC-129;
NCIt definition : An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against
the tumor-associated antigen (TAA) carcinoembryonic antigen (CEA; carcinoembryonic
antigen-related cell adhesion molecule 5; CEACAM5) and the immune checkpoint regulator
carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6; CEACAM-6; CD66c)
and conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin
E (MMAE), with potential antineoplastic and immune checkpoint inhibitory activities.
Upon administration of anti-CEA/CEACAM6 ADC EBC-129, the monoclonal antibody moiety
targets and binds to a specific glycosylation site that is conserved on both CEA and
CEACAM6 expressed on tumor cells. Upon binding and internalization, MMAE is released
where it targets and binds to tubulin and inhibits microtubule polymerization. This
results in G2/M phase cell cycle arrest and apoptosis in CEA and/or CEACAM6-expressing
tumor cells. CEA, a member of the CEA family of proteins that plays a key role in
cell migration, cell invasion, and cell adhesion, is overexpressed by a variety of
cancer cell types. CEACAM6, an immune checkpoint receptor, is associated with tumor-mediated
immune suppression. Elevated CEACAM6 expression is associated with advanced tumor
stages and poor prognosis.;
Molecule name : EBC-129; EBC 129;
NCI Metathesaurus CUI : CL1907331;
Origin ID : C200045;
concept_is_in_subset
- has_target
